Leveraging mathematical modeling to analyze nonadherence for hydroxyurea therapy in sickle cell disease

被引:0
|
作者
Pandey, Akancha [1 ,5 ]
Raja, Rubesh [1 ]
Estepp, Jeremie H. [2 ,3 ,6 ]
Ramkrishna, Doraiswami [1 ,4 ]
机构
[1] Purdue Univ, Davidson Sch Chem Engn, W Lafayette, IN USA
[2] St Jude Childrens Res Hosp, Dept Hematol, Memphis, TN USA
[3] St Jude Childrens Res Hosp, Dept Global Pediat Med, Memphis, TN USA
[4] Purdue Univ, Davidson Sch Chem Engn, 480 Stadium Mall Dr, W Lafayette, IN 47907 USA
[5] AbbVie Inc, South San Francisco, CA USA
[6] Agios Pharmaceut, Cambridge, MA USA
来源
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY | 2023年 / 12卷 / 06期
关键词
ADHERENCE RATE THRESHOLD; QUALITY-OF-LIFE; ALTERNATE-DAY; ANEMIA; CHILDREN; HYDROXYCARBAMIDE; NONCOMPLIANCE; ATORVASTATIN; MULTICENTER; MORBIDITY;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nonadherence is common in individuals with sickle cell disease (SCD) on hydroxyurea therapy and can be observed with waning improvements in hematologic parameters or biomarkers like mean cell volume and fetal hemoglobin level over time. We modeled the impact of hydroxyurea nonadherence on longitudinal biomarker profiles. We estimated the potential nonadherent days in individuals exhibiting a drop in biomarker levels by modifying the dosing profile using a probabilistic approach. Incorporating additional nonadherence using our approach besides existing ones in the dosing profile improves the model fits. We also studied how different patterns in adherence give rise to various physiological profiles of biomarkers. The key finding is consecutive days of nonadherence are less favorable than when nonadherence is interspersed. These findings improve our understanding of nonadherence and how appropriate intervention strategies can be applied for individuals with SCD susceptible to the severe impacts of nonadherence.
引用
收藏
页码:748 / 757
页数:10
相关论文
共 50 条
  • [41] Effect of hydroxyurea therapy on resting energy expenditure in children with sickle cell disease
    Fung, EB
    Barden, EM
    Kawchak, DA
    Zemel, BS
    Ohene-Frempong, K
    Stallings, VA
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2001, 23 (09) : 604 - 608
  • [42] Clinic Attendance of Youth With Sickle Cell Disease on Hydroxyurea Treatment
    Ingerski, Lisa M.
    Arnold, Trisha L.
    Banks, Gabrielle
    Porter, Jerlym S.
    Wang, Winfred C.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2017, 39 (05) : 345 - 349
  • [43] Higher oxygen saturation with hydroxyurea in paediatric sickle cell disease
    van Geyzel, Lisa
    Arigliani, Michele
    Inusa, Baba
    Singh, Bethany
    Kozlowska, Wanda
    Chakravorty, Subarna
    Bossley, Cara J.
    Ruiz, Gary
    Rees, David
    Gupta, Atul
    ARCHIVES OF DISEASE IN CHILDHOOD, 2020, 105 (06) : 575 - 579
  • [44] Value of hydroxyurea therapy in children severely affected with sickle cell disease.
    Oury, AP
    Hoyoux, C
    Dresse, MF
    Chantraine, JM
    ARCHIVES DE PEDIATRIE, 1997, 4 (09): : 839 - 844
  • [45] Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent
    Rigano, Paolo
    De Franceschi, Lucia
    Sainati, Laura
    Piga, Antonio
    Piel, Frederic B.
    Cappellini, Maria Domenica
    Fidone, Carmelo
    Masera, Nicoletta
    Palazzi, Giovanni
    Gianesin, Barbara
    Forni, Gian Luca
    BLOOD CELLS MOLECULES AND DISEASES, 2018, 69 : 82 - 89
  • [46] Determinants of hydroxyurea use among doctors, nurses and sickle cell disease patients in Nigeria
    Isa, Hezekiah Alkali
    Nnebe-Agumadu, Uche
    Nwegbu, Maxwell M.
    Okocha, Emmanuel C.
    Chianumba, Reuben, I
    Brown, Biobele J.
    Asala, Samuel A.
    Peprah, Emmanuel
    Nnodu, Obiageli E.
    PLOS ONE, 2022, 17 (11):
  • [47] Proteinuria in adults with sickle-cell disease: the role of hydroxycarbamide(hydroxyurea) as a protective agent
    Silva Junior, Geraldo B.
    Vieira, Ana Patricia F.
    Couto Bem, Amanda X.
    Alves, Marilia P.
    Meneses, Gdayllon C.
    Martins, Alice M. C.
    Araujo, Sonia M. H. A.
    Liborio, Alexandre V.
    Daher, Elizabeth F.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2014, 36 (04) : 766 - 770
  • [48] Survival and mortality among users and non-users of hydroxyurea with sickle cell disease
    Rodrigues de Araujo, Olinda Maria
    Ivo, Maria Lucia
    Ferreira Junior, Marcos Antonio
    Jardim Cury Pontes, Elenir Rose
    Goncalves Pacce Bispo, Ieda Maria
    Luna de Oliveira, Eveny Cristine
    REVISTA LATINO-AMERICANA DE ENFERMAGEM, 2015, 23 (01): : 67 - 73
  • [49] Patient-focused inquiry on hydroxyurea therapy adherence and reasons for discontinuation in adults with sickle cell disease
    Bradford, Christopher
    Miodownik, Hope
    Thomas, Merin
    Ogu, Ugochi O.
    Minniti, Caterina P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : E93 - E95
  • [50] Introduction of Hydroxyurea Therapy to a Cohort of Sickle Cell Patients in Northern Haiti
    Paul-Hanna, Michele
    Joseph, Wesline
    Mondesir, Woodgina
    Faustino, Edward V. S.
    Canarie, Michael F.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2022, 44 (07) : 351 - 353